+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020

  • ID: 4911710
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 42 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Firebrick Pharma Pty Ltd
  • Karo Pharma AB
  • Orbis Biosciences Inc
  • Pfizer Inc
  • Tris Pharma Inc
  • MORE
Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020, provides an overview of the Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline landscape.

Nasopharyngitis also known as common cold is an infectious, inflammatory condition that affects the throat and nasal passages. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Nasopharyngitis (Common Cold) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Firebrick Pharma Pty Ltd
  • Karo Pharma AB
  • Orbis Biosciences Inc
  • Pfizer Inc
  • Tris Pharma Inc
  • MORE
  • Introduction
  • Report Coverage
  • Nasopharyngitis (Common Cold) - Overview
  • Nasopharyngitis (Common Cold) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Nasopharyngitis (Common Cold) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
  • Charleston Laboratories Inc
  • Firebrick Pharma Pty Ltd
  • Karo Pharma AB
  • Orbis Biosciences Inc
  • Pfizer Inc
  • Sanotize Research And Development Corp
  • Tris Pharma Inc
  • Nasopharyngitis (Common Cold) - Drug Profiles
  • Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • guaifenesin ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nasopharyngitis (Common Cold) - Dormant Projects
  • Nasopharyngitis (Common Cold) - Discontinued Products
  • Nasopharyngitis (Common Cold) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
  • Oct 10, 2013: Spriaso completes FDA Meeting on Tuxarin ER
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Nasopharyngitis (Common Cold), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories Inc, H1 2020
  • Nasopharyngitis (Common Cold) - Pipeline by Firebrick Pharma Pty Ltd, H1 2020
  • Nasopharyngitis (Common Cold) - Pipeline by Karo Pharma AB, H1 2020
  • Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences Inc, H1 2020
  • Nasopharyngitis (Common Cold) - Pipeline by Pfizer Inc, H1 2020
  • Nasopharyngitis (Common Cold) - Pipeline by Sanotize Research And Development Corp, H1 2020
  • Nasopharyngitis (Common Cold) - Pipeline by Tris Pharma Inc, H1 2020
  • Nasopharyngitis (Common Cold) - Dormant Projects, H1 2020
  • Nasopharyngitis (Common Cold) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Nasopharyngitis (Common Cold), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Charleston Laboratories Inc
  • Firebrick Pharma Pty Ltd
  • Karo Pharma AB
  • Orbis Biosciences Inc
  • Pfizer Inc
  • Sanotize Research And Development Corp
  • Tris Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll